LRRC15 antibody-drug conjugates show promise as osteosarcoma therapeutics in preclinical studies.

ABSTRACT:

Background

Osteosarcoma (OS), the most common bone tumor in children and adolescents, has high rates of metastasis leading to poor survival. Leucine-rich repeat containing 15 (LRRC15), a transmembrane protein whose expression is modulated by TGFβ, was recently shown to be highly expressed on the surface of OS tumor cells. Here, we evaluate a novel antibody-drug conjugate (ADC) targeting LRRC15 in OS human cell lines and murine xenografts. We compare this new ADC, which is conjugated to the anthracycline derivative PNU-159682 (PNU), to a previously studied LRRC15 ADC that is conjugated to the tubulin inhibitor monomethyl auristatin E (MMAE), since anthracyclines are standard of care in OS.

Procedure

We evaluated LRRC15 expression in OS cells using Western blots and flow cytom

SUBMITTER: Slemmons KK 

PROVIDER: S-EPMC9137401 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature